---
symbol: "LLY"
name: "Eli Lilly"
date: 2026-10-01
change_pct: -3.252991741109044
direction: "down"
event_type: "other"
url: "https://perplo.app/why/LLY/2026-10-01"
updated_at: 2026-10-01T17:06:21.608Z
---

# Why Eli Lilly (LLY) fell 3.25% on October 1, 2026

Eli Lilly (LLY) fell 3.25% on October 1, 2026 — Mixed obesity trial data weighs on pipeline outlook.

## What happened

Eli Lilly's weight-loss drug pipeline delivered mixed trial data, flagged by Wall Street as a near-term overhang on the obesity drug class.

## Why it moved

Mixed efficacy or safety readouts in obesity drug trials compress investor expectations for peak sales and margin potential, pressuring multiple expansion and forward guidance; the trial result directly challenges…

## Why it matters

Obesity drug pipelines are among the highest-conviction growth drivers in Healthcare & Biotech, but clinical setbacks or competitive erosion can rapidly reset valuation; mixed data suggests Lilly's competitive…

## What would break the thesis

If later data clarifies that efficacy or safety is stronger than the headline suggests, or if management demonstrates a credible path to parity with Novo Nordisk's Ozempic, the conviction can reverse.

## Sources

- [Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data](https://www.cnbc.com/2026/09/30/wall-streets-strong-quarter-plus-lillys-mixed-obesity-drug-trial-data.html) — CNBC

---

Trade LLY perpetual futures 24/7 onchain: https://perplo.app/asset/LLY